The quarter cleared both the internal and published bar by a wide margin. Adjusted EPS was $2.37 versus a published consensus of roughly $2.08, while revenue was $872.3 million versus roughly $839.8 million expected. The filing also says results exceeded management’s expectations, but the more important point is that the gap was visible in both earnings and sales—not just a favorable mix or tax benefit. (Financial Highlights; Income Statement)
| Metric | Q2 2026 | Q2 2025 | Versus expectation |
|---|---|---|---|
| Revenue | $872.3M | $766.5M | ~$839.8M consensus |
| Organic revenue growth | 12.7% | — | Q2 guide: 7.0%-9.6% |
| Adjusted diluted EPS | $2.37 | $1.84 | ~$2.08 consensus |
| Adjusted operating margin | 22.6% | 20.3% | +230 bps YoY |
| Gross margin | 37.7% | 35.7% | +200 bps YoY |
| West Vantage organic growth | 0.8% | — | Margin impacted by cyber incident |
The growth engine was substantially stronger than the headline average suggests. Proprietary Products, representing 83% of sales, grew 15.5% organically, led by HVP Components at 18.4% and HVP Delivery Devices at 29.2%. Biologics grew 29.2% organically and accounted for 43% of company revenue, while GLP-1-related revenue represented 18% of sales. (Segment results — Proprietary Products; Revenue by Product Category; Revenue by Market Group)
Management converted the beat into a meaningful outlook upgrade. Full-year revenue guidance moved to $3.345-$3.380 billion from the prior $3.295-$3.350 billion range, and adjusted EPS guidance rose to $8.85-$9.05 from $8.40-$8.75. The new Q3 EPS guide of $2.14-$2.24 also sits modestly above the roughly $2.12 published expectation, while Q3 revenue guidance of $820-$835 million is above the roughly $814.7 million consensus. (2026 / Q3 Guidance; Reconciliation of Adjusted-Diluted EPS Guidance)
The main offset is execution risk in the lower-growth segment and weaker cash conversion. West Vantage grew only 0.8% organically, and its operating margin fell to 8.6% from 12.1% as the May 2026 cyber incident weighed on gross margin. First-half operating cash flow fell to $213.9 million from $306.5 million, while free cash flow declined to $128.0 million from $160.0 million, despite lower capital spending. The company also spent $454.3 million on share repurchases, leaving cash at $435.8 million versus $791.3 million at year-end. (Segment results — West Vantage; Cash Flow statement; Balance Sheet)
Net read: a genuine earnings beat with upgraded expectations, not merely a strong-looking quarter. The magnitude of the sales and EPS upside, broad strength across biologics and HVP products, and higher full-year targets outweigh the cyber-related margin pressure and weaker first-half cash generation. The result was partly known in direction because Q1 had already established strong momentum and raised guidance, but this filing materially increased the size of the expected earnings path. (Q2 Financial Highlights; 2026 Guidance)
Read the original 8-K on SEC EDGAR ↗